BloodStream

BloodStream is an entertaining and informational podcast for the bleeding disorders community. Each week, hemophilia patient Patrick James Lynch and former non-profit director Amy Board are joined by advocacy leaders, medical experts, and other guests to discuss the latest news, scientific advancements, policy initiatives, and so much more. Subscribe wherever you listen, or search BloodStream Podcast on YouTube to catch every episode there. Produced by Believe Limited. Presenting sponsor: Takeda.

  1. How the Patient Perspective Led to a Hemophilia Medical Breakthrough

    6h ago

    How the Patient Perspective Led to a Hemophilia Medical Breakthrough

    Please see https://www.pfi.sr/HYMPAVZI_PI for Full PI. #HYMPAVZISponsored William S. Somers, Ph.D., was a biotherapeutics research and development leader with more than 30 years of experience across biotechnology and pharmaceutical organizations, including Pfizer. As a scientist living with hemophilia, Dr. Somers played a key role in driving the patient-centric and purposeful design of HYMPAVZI (marstacimab-hncq). This episode will explore how the patient perspective influenced the scientific journey, with a special focus on Will's research and why it was personally important for him to bring HYMPAVZI to people with hemophilia. HYMPAVZI may cause serious side effects, including blood clots (thromboembolic events). HYMPAVZI may increase the risk for your blood to clot in blood vessels in your arm, leg, lung, or head, which can be life-threatening. To learn more about this risk and additional safety information visit HYMPAVZI.com. This post is directed to a U.S. audience and may not be suitable outside of the U.S. This video is intended to be viewed as it was originally produced in partnership with Pfizer. Remember, this content is for educational purposes only and does not replace discussions with a healthcare provider. PP-HYM-USA-1267 Show Notes: For safety information visit: https://labeling.pfizer.com/ShowLabeling.aspx?id=20916&Section=PPI For information on how to navigate your treatment journey, visit the Shared Decision-making Guide here. Listen and subscribe where you get your podcasts! #Hemophilia IMPORTANT SAFETY INFORMATION Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products or "bypassing agents" (products that help blood clot but work in a different way than HYMPAVZI). Your healthcare provider may prescribe factor VIII or factor IX medicines or bypassing agents to treat episodes of breakthrough bleeding during your treatment with HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when to use these medicines and the prescribed dose during your treatment with HYMPAVZI. Do not use additional doses of HYMPAVZI to treat breakthrough bleeds. Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you: have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery. have a severe short-term (acute) illness such as an infection or injury. have been told that you have a risk for blood clots. are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI. Use effective birth control (contraception) during treatment with HYMPAVZI and for at least 2 months after the last dose of HYMPAVZI. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI. are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. If you inject too much HYMPAVZI, call your healthcare provider or the Poison Help Line at 1-800-222-1222 or go to the nearest hospital emergency room right away. What are the possible side effects of HYMPAVZI? HYMPAVZI may cause serious side effects, including: blood clots (thromboembolic events). HYMPAVZI may increase the risk for your blood to clot in blood vessels in your arm, leg, lung, or head, which can be life-threatening. Blood clots have happened in people using HYMPAVZI. You may have an increased risk of blood clots if you have certain risk factors. Stop using HYMPAVZI and get medical help right away if you develop any of these signs or symptoms of blood clots: swelling or pain in your arms or legs redness or discoloration in your arms or legs shortness of breath pain in chest or upper back fast heart rate cough up blood feeling faint headache numbness in your face eye pain or swelling trouble seeing allergic reactions. HYMPAVZI may cause allergic reactions, including rash and itching. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction: swelling of your face, lips, mouth, or tongue trouble breathing wheezing dizziness or fainting  fast heartbeat or pounding in your chest  sweating The most common side effects of HYMPAVZI include: swelling, hardening, redness, bruising, bleeding, and pain at injection site headache fever joint pain  diarrhea  itching  rash  These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. What is HYMPAVZI? HYMPAVZI is a prescription medicine used regularly to prevent or reduce the frequency of bleeding episodes in adults and children 6 years of age and older with: hemophilia A with or without factor VIII inhibitors, or hemophilia B with or without factor IX inhibitors. It is not known if HYMPAVZI is safe and effective in people receiving ongoing Immune Tolerance Induction (ITI).  It is not known if HYMPAVZI is safe and effective in children younger than 6 years of age.

    21 min
  2. How the Patient Perspective Led to a Hemophilia Medical Breakthrough

    May 21

    How the Patient Perspective Led to a Hemophilia Medical Breakthrough

    Please see https://www.pfi.sr/HYMPAVZI_PI  for Full PI​ #HYMPAVZISponsored William S. Somers, Ph.D. is a biotherapeutics research and development leader with more than 30 years of experience across biotechnology and pharmaceutical organizations, including Pfizer.​ As a scientist living with hemophilia, Dr. Somers played a key role in driving the patient-centric and purposeful design of HYMPAVZI (marstacimab-hncq). This episode will explore how the patient perspective influenced the scientific journey, with a special focus on Will's research and why it was personally important for him to bring HYMPAVZI to people with hemophilia. To learn more and for safety information, visit HYMPAVZI.com.​ This post is directed to a U.S. audience and may not be suitable outside of the U.S. This video is intended to be viewed as it was originally produced in partnership with Pfizer. Remember, this content is for educational purposes only and is not intended to replace discussions with a healthcare provider.​ PP-HYM-USA-1071​ Show Notes:​ For prescribing information visit pfi.sr/HYMPAVZI_PI​ For information on how to navigate your treatment journey visit the shared decision-making guide here. Listen and subscribe where you get your podcasts!​ #Hemophilia HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HYMPAVZI safely and effectively. See full prescribing information for HYMPAVZI. HYMPAVZI (marstacimab-hncq) injection, for subcutaneous use Initial U.S. Approval: 2024 INDICATIONS AND USAGE HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. DOSAGE AND ADMINISTRATION See Full Prescribing Information for important dosing and administration instructions.  The recommended dosage of HYMPAVZI is: Loading dose: 300 mg (two 150 mg injections) by subcutaneous injection Maintenance dose: One week after the loading dose, initiate maintenance dosing of 150 mg every week by subcutaneous injection on the same day each week, at any time of day. Dose adjustment to 300 mg subcutaneous injection weekly can be considered. Factor VIII and factor IX products can be administered for the treatment of breakthrough bleeds in patients receiving HYMPAVZI. Do not use additional doses of HYMPAVZI to treat breakthrough bleeds.  Temporarily discontinue HYMPAVZI before major surgery.  DOSAGE FORMS AND STRENGTHS Injection: 150 mg/mL in a single-dose prefilled syringe  Injection: 150 mg/mL in a single-dose prefilled pen  CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS Thromboembolic Events: Thromboembolic events may occur. Interrupt HYMPAVZI prophylaxis if symptoms occur. Hypersensitivity: Hypersensitivity reactions may occur. In the event of a severe allergic reaction, discontinue HYMPAVZI. Embryofetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. ADVERSE REACTIONS Adverse reactions reported in ≥3% of HYMPAVZI-treated patients were injection site reaction, headache, and pruritus.  To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 12/2025

    21 min
4.9
out of 5
43 Ratings

About

BloodStream is an entertaining and informational podcast for the bleeding disorders community. Each week, hemophilia patient Patrick James Lynch and former non-profit director Amy Board are joined by advocacy leaders, medical experts, and other guests to discuss the latest news, scientific advancements, policy initiatives, and so much more. Subscribe wherever you listen, or search BloodStream Podcast on YouTube to catch every episode there. Produced by Believe Limited. Presenting sponsor: Takeda.

More From BloodStream Media

You Might Also Like